Sun Pharma To Acquire Checkpoint Therapeutics: Shares Rise 2% | The Bengaluru Live

Sun Pharma to Acquire Checkpoint Therapeutics: Shares Rise 2%

Atul Chaturvedi 10 March 2025 1 minute read

📘 Read this story in Kannada

In a recent development, shares of Sun Pharmaceutical Industries climbed over 2% during morning trade, driven by the announcement of a significant acquisition.

Atul Chaturvedi

Administrator

Atul Chaturvedi boasts over 25 years of experience in the media industry, having held positions at esteemed organizations such as Republic TV, Times Network's Mirror Now News Channel, Times of India, Bangalore Mirror, Rajasthan Patrika Hindi newspaper, and Sakal newspaper.

View All Posts

Atul Chaturvedi

President Accepts Dharmendra Pradhan’s Resignation; Pralhad Joshi Given Additional Charge of Education Ministry

Dharmendra Pradhan Resigns as Union Education Minister, Cites NEET-UG Controversy and Youth Interest

Minister Yathindra Siddaramaiah Reviews KUWSDB Projects, Orders Survey of All STP Units in Karnataka

Karnataka High Court Grants Interim Bail to Vinay Kulkarni, Stays Life Sentence in Yogesh Gowda Murder Case

Karnataka Bans Sale of Junk Food in Schools, Colleges and Within 50-Metre Radius

Karnataka Bandh Called on August 13 Over Cauvery Water Release to Tamil Nadu

GBA Directs Vacant Site Owners in Bengaluru to Clear Waste by August 15 or Face Penalties

Pejawar Seer Sri Vidyendra Tirtha to Observe 15th Chaturmasya Vrata in Bengaluru from August 8

Bengaluru Water Board Fines 692 Consumers for Misuse of Cauvery Drinking Water

You may have missed

Karnataka High Court Grants Interim Bail to Vinay Kulkarni, Stays Life Sentence in Yogesh Gowda Murder Case

Karnataka Bans Sale of Junk Food in Schools, Colleges and Within 50-Metre Radius

Karnataka Bandh Called on August 13 Over Cauvery Water Release to Tamil Nadu

GBA Directs Vacant Site Owners in Bengaluru to Clear Waste by August 15 or Face Penalties

About us

Useful Links

Recent News

About the Author

Leave a Reply Cancel reply

Related Stories

You may have missed